Navigation Links
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/30/2008

-- Third Sequential Profitable Quarter --

-- Conference Call on Monday, March 31, 2008 at 9:00 a.m. ET --

BEIJING, March 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced unaudited financial results for the three months and twelve months ended December 31, 2007.

Highlights

-- Record full year 2007 sales of $33.5 million, up 118% year-over-year

-- Record full year 2007 net income of $7.7 million, or $0.19 per share

-- Fourth quarter 2007 sales increased 49% year-over-year to $9.2 million

-- Fourth quarter 2007 operating income rose 460% year-over-year to

$3.3 million

-- Fourth quarter 2007 net income increased to $2.0 million, or $0.05

per share

-- Reported positive preliminary Phase II results for pandemic influenza

(H5N1) whole viron vaccine

-- Sold 5.12 million doses of Healive(R) in 2007, up from 2.6 million

in 2006

-- Sold 1.59 million doses of Anflu(R) in 2007, up from 77,000 doses in

in 2006

Mr. Weidong Yin, Chairman, President and CEO, stated, ''2007 was a record year for Sinovac from a commercialization and a clinical development standpoint. Exceeding our internal projections for year-over-year sales growth, our 2007 sales increased 118%, due to higher than anticipated sales of our lead products, Healive(R), our inactivated hepatitis A vaccine, and Anflu(R), our seasonal influenza vaccine, based on the proactive efforts of our sales organization across China. In addition, we entered a promotion agreement with GSK China for our seasonal influenza vaccine, Anflu(R), and successfully launched a marketing campaign that yielded sales in the second half of the year. We advanced the clinical development of our pandemic influenza vaccine formulations. We successfully completed the Phase II trial of our whole viron vaccine in 2007 that led to
'/>"/>

SOURCE Sinovac Biotech Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... 2014 The report "Chocolate, Cocoa Beans, ... Prices, Geography Trend and Forecast (2011 - 2016)," ... geography and studies the major market drivers, restraints, and ... and Asia. , The global chocolate market is expected ... in 2016 at an estimated CAGR of 2.7% from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... BASEL, Switzerland, Dec. 5 Roche (SWX:,ROG.VX; RO.S) announced ... (Nasdaq: VMSI ), as required by Ventana,s bylaws, ... of directors at,Ventana,s 2008 annual stockholders meeting., On ... acquire all of the,outstanding common shares of Ventana for ...
... Cost, Savings and Avoidance of Approximately $1.5 Billion by 2010 and Incur, Associated ... ... 11% Increase in Indicative Dividend for 2008 and Declares ... Quarterly Dividend, * Revises 2007 Full-Year GAAP EPS Guidance to ...
... January for lead antibody program ... ... Inc. (TSX:,ARI), a biotechnology company discovering and developing the next wave of,antibody ... transfer agreement for its CD44 Cancer,Stem Cell antibody with Avid Bioservices, a ...
Cached Biology Technology:Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 2Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 3Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 4Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 5Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 6Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 7Roche to Nominate Independent Directors for Election at Ventana's 2008 Annual Stockholders Meeting 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 2Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 3Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 4Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 5Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 6Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 7Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 9Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 10Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 11ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody 2ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody 3
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... 16, 2013) A team of American and Chinese conservationists ... counted nearly 1,000 wild yaks from a remote area of ... this species, which was decimated by overhunting in the mid ... rugged area called Hoh Xil a national nature reserve ...
... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new journal, Journal ... ). JUOGR is to publish ... practices in the area of evaluation, development and management ...
... $14 million from the William & Nancy Thompson Family ... County, UC Irvine is helping lead the charge against ... in the U.S. autism., The funding created the ... which will provide unparalleled access to assessment, diagnosis, care ...
Cached Biology News:Yaks are back 2UCI research turns the corner on autism 2UCI research turns the corner on autism 3
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: